Literature DB >> 26657834

Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.

A Ruggeri1, M Labopin1,2, F Ciceri3, M Mohty1,2, A Nagler2,4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26657834     DOI： 10.1038/bmt.2015.305

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

Review 1.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.

Authors:  Myriam Labopin; Annalisa Ruggeri; Norbert Claude Gorin; Eliane Gluckman; Didier Blaise; Lionel Mannone; Noel Milpied; Ibrahim Yakoub-Agha; Eric Deconinck; Mauricette Michallet; Nathalie Fegueux; Gerard Socié; Stephanie Nguyen; Jean Yves Cahn; Thierry de Revel; Federico Garnier; Catherine Faucher; Namik Taright; Chantal Kenzey; Fernanda Volt; Dominique Bertrand; Mohamad Mohty; Vanderson Rocha
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

3.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

5.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.

Authors:  Mary Eapen; Vanderson Rocha; Guillermo Sanz; Andromachi Scaradavou; Mei-Jie Zhang; William Arcese; Anne Sirvent; Richard E Champlin; Nelson Chao; Adrian P Gee; Luis Isola; Mary J Laughlin; David I Marks; Samir Nabhan; Annalisa Ruggeri; Robert Soiffer; Mary M Horowitz; Eliane Gluckman; John E Wagner
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

6.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.

Authors:  K Atkinson; M M Horowitz; R P Gale; D W van Bekkum; E Gluckman; R A Good; N Jacobsen; H J Kolb; A A Rimm; O Ringdén
Journal:  Blood       Date:  1990-06-15       Impact factor: 22.113

7.  Resilience, health, and quality of life among long-term survivors of hematopoietic cell transplantation.

Authors:  Abby R Rosenberg; Karen L Syrjala; Paul J Martin; Mary E Flowers; Paul A Carpenter; Rachel B Salit; K Scott Baker; Stephanie J Lee
Journal:  Cancer       Date:  2015-08-19       Impact factor: 6.860

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.

Authors:  K M Sullivan; H M Shulman; R Storb; P L Weiden; R P Witherspoon; G B McDonald; M M Schubert; K Atkinson; E D Thomas
Journal:  Blood       Date:  1981-02       Impact factor: 22.113

Review 10.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

Authors:  Boglarka Gyurkocza; Brenda M Sandmaier
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113
View more
  51 in total

1.  Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Authors:  P Kongtim; K Adekola; D R Milton; R Ramlal; A Jimenez; J Chen; G Rondon; S Ahmed; P Kebriaei; O Betul; C M Hosing; U Popat; I Khouri; E Jabbour; J E Cortes; H M Kantarjian; R E Champlin; S O Ciurea
Journal:  Leukemia       Date:  2017-04-12       Impact factor: 11.528

2.  Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.

Authors:  Mi Kwon; Rebeca Bailén; María Jesús Pascual-Cascón; Ana Isabel Gallardo-Morillo; Abel García Sola; Pascual Balsalobre; Laura Solán; Nieves Dorado; Cristina Muñoz; David Serrano; Carolina Martínez-Laperche; Ismael Buño; Javier Anguita; José Luis Díez-Martin
Journal:  Blood Adv       Date:  2019-11-12

3.  Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years.

Authors:  Vipul Sharad Sheth; Victoria Potter; Shreyans A Gandhi; Austin Gladston Kulasekararaj; Hugues de Lavallade; Petra Muus; Antonio Pagliuca; Carmel F M Rice; Varun Mehra; Francesco Grimaldi; Shafqat Inam; Linda D Barber; Ghulam J Mufti; Judith C Marsh
Journal:  Blood Adv       Date:  2019-10-22

4.  The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.

Authors:  Amy K Keating; Jurgen Langenhorst; John E Wagner; Kristin M Page; Paul Veys; Robert F Wynn; Heather Stefanski; Reem Elfeky; Roger Giller; Richard Mitchell; Filippo Milano; Tracey A O'Brien; Ann Dahlberg; Colleen Delaney; Joanne Kurtzberg; Michael R Verneris; Jaap Jan Boelens
Journal:  Blood Adv       Date:  2019-04-09

5.  A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.

Authors:  Jiro Inagaki; Reiji Fukano; Maiko Noguchi; Jun Okamura
Journal:  Int J Hematol       Date:  2017-02-15       Impact factor: 2.490

6.  PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

Authors:  Peter Dreger; Anna Sureda; Kwang Woo Ahn; Mary Eapen; Carlos Litovich; Herve Finel; Ariane Boumendil; Ajay Gopal; Alex F Herrera; Christoph Schmid; José Luis Diez-Martin; Ephraim Fuchs; Javier Bolaños-Meade; Mahasweta Gooptu; Monzr M Al Malki; Luca Castagna; Stefan O Ciurea; Alida Dominietto; Didier Blaise; Fabio Ciceri; Johanna Tischer; Paolo Corradini; Silvia Montoto; Stephen Robinson; Zafer Gülbas; Mehdi Hamadani
Journal:  Blood Adv       Date:  2019-02-12

7.  Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Authors:  Arnon Nagler; Myriam Labopin; Bhagirathbhai Dholaria; Riitta Niittyvuopio; Johan Maertens; Xavier Poiré; Jan Cornelissen; Péter Reményi; Jean Henri Bourhis; Yves Beguin; Ram Malladi; Tessa Kerre; Wilfried Schroyens; Bipin N Savani; Mohamad Mohty
Journal:  Blood Adv       Date:  2019-07-09

8.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Authors:  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

9.  Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.

Authors:  Annalisa Ruggeri; Yuqian Sun; Myriam Labopin; Andrea Bacigalupo; Francesca Lorentino; William Arcese; Stella Santarone; Zafer Gülbas; Didier Blaise; Giuseppe Messina; Ardeshi Ghavamzadeh; Florent Malard; Benedetto Bruno; Jose Luis Diez-Martin; Yener Koc; Fabio Ciceri; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

10.  Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.

Authors:  Rebeca Bailén; Mi Kwon; María Jesús Pascual-Cascón; Christelle Ferrà; Jaime Sanz; Anabel Gallardo-Morillo; Abel García-Sola; Anna Torrent; María José Jiménez-Lorenzo; José Luis Piñana; Juan Montoro; Gillen Oarbeascoa; Nieves Dorado; Ignacio Gómez-Centurión; Cristina Muñoz; Carolina Martínez-Laperche; Javier Anguita; Ismael Buño; José Luis Díez-Martín
Journal:  Ann Hematol       Date:  2020-11-02       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.